

MEDIA CONTACT:
Venus TSANG
Venus.tsang@gilead.com

FOR IMMEDIATE RELEASE

GILEAD SCIENCES APPOINTS JAE YEON CHOI AS NEW GENERAL MANAGER FOR KOREA

– Ms. Choi brings over 18 years’ experience in the pharmaceutical industry. –

– Former MSD Taiwan Managing Director has strong track record of leadership roles in commercial, access, policy and HR functions spanning diverse regions including US, China, Taiwan, and Korea. –

SINGAPORE, 14 September 2023 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the appointment of Ms. Jae Yeon Choi as General Manager, Korea, effective 1st October 2023.

Ms. Choi will be responsible for managing Gilead’s Korea operations and driving business development across HIV, viral hepatitis, COVID-19, fungal infections, and cancer. In addition, she will support Gilead's commitment to enhancing wider health and community impact projects in Korea.

Ms. Choi graduated with an MBA from Kellogg School of Business, Northwestern University. She brings nearly two decades of experience across a variety of leadership roles in the pharmaceutical industry, including commercial, HR, access and policy, spanning diverse geographical regions including US, China, Taiwan, and Korea.

She joins Gilead from MSD, where she served as Managing Director MSD Taiwan, having driven double digit business growth for two consecutive years. Ms. Choi joined MSD in 2017 as External Affairs Lead, Korea, and subsequently took on the role of Oncology Business Unit Director in Korea, developing and building a team that achieved exceptional performance in Immuno-oncology. Prior to MSD, Ms. Choi spent eleven years at Eli Lilly last serving as Marketing Director for Eli Lilly in Korea.

"I am thrilled to join the team at Gilead in Korea and support a shared mission of saving and improving people’s lives in Asia," Ms. Choi said. "I have always believed strongly in the noble mission of the pharmaceutical industry and how public-private partnerships can revolutionize healthcare for all. Putting patients at the heart of everything we do is vital, which is why I am honored to join a company that is so well known for its commitment to the communities it serves. I am looking forward to working with the team in Korea and colleagues across Asia to deliver better care solutions for people living with HIV, viral hepatitis, fungal conditions, and cancer."

With this appointment, Ms. Choi will become a member of the Asia 5 Leadership Team, reporting to Dustin Haines, Vice President and General Manager Asia, Middle East, and Turkey.

"I am delighted that Ms. Choi will be joining the Gilead Asia team at such an important time," said Mr. Haines. "Ms. Choi’s motivation to make a positive impact on patients’ lives closely mirrors our own focus of going beyond medicine, to remedy health inequities and break down barriers to care."

“She is a versatile and adaptable leader with demonstrated success in a variety of functions. Her humble, team focused managerial approach has rightly earned her numerous business awards over the years and I am confident her commitment to partnership will further strengthen our presence in Korea."

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

###

For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on X (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-30.